Dapa 10 mg vs Placebo: Subjects Included in the Endpoint of Cardiovascular Death
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0738 | 0.0651 | 0.0835 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0833 | 0.0742 | 0.0935 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00955 | -0.0229 | 0.00379 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.885 | 0.747 | 1.05 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.876 | 0.729 | 1.05 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Dapa 10 mg than on Placebo | 105 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Dapa 10 mg | Dapagliflozin 10 mg tablets administered once daily per oral use | 231 | 3,131 | OG000 | ClinicalTrials.gov |
| Group 2 | Placebo | Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use | 261 | 3,132 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Subjects Included in the Endpoint of Cardiovascular Death | ClinicalTrials.gov |
| Description | Secondary efficacy~The analysis was assessed on Full Analysis Set, including deaths occurring on or prior to Primary Analysis Censoring Date. | ClinicalTrials.gov |
| Time frame | Up to 42.1 months | ClinicalTrials.gov |
| Population | Full analysis set | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. | ClinicalTrials.gov |
| NCT number | NCT03619213 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Heart Failure With Preserved Ejection Fraction | ClinicalTrials.gov |
| Interventions | Dapagliflozin, Placebo | ClinicalTrials.gov |
| Lead sponsor | AstraZeneca | ClinicalTrials.gov |
| Results first posted | 2023-07-11 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT03619213?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.